331 related articles for article (PubMed ID: 33427211)
1. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.
Kato S; Okamura R; Adashek JJ; Khalid N; Lee S; Nguyen V; Sicklick JK; Kurzrock R
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33427211
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.
Kato S; Schwaederle M; Daniels GA; Piccioni D; Kesari S; Bazhenova L; Shimabukuro K; Parker BA; Fanta P; Kurzrock R
Cell Cycle; 2015; 14(8):1252-9. PubMed ID: 25695927
[TBL] [Abstract][Full Text] [Related]
3. Targeting CDK4 and CDK6: From Discovery to Therapy.
Sherr CJ; Beach D; Shapiro GI
Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
[TBL] [Abstract][Full Text] [Related]
4. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
5. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
6. The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
Du Q; Guo X; Wang M; Li Y; Sun X; Li Q
J Hematol Oncol; 2020 May; 13(1):41. PubMed ID: 32357912
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
10. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
[No Abstract] [Full Text] [Related]
11. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
12. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Gelbert LM; Cai S; Lin X; Sanchez-Martinez C; Del Prado M; Lallena MJ; Torres R; Ajamie RT; Wishart GN; Flack RS; Neubauer BL; Young J; Chan EM; Iversen P; Cronier D; Kreklau E; de Dios A
Invest New Drugs; 2014 Oct; 32(5):825-37. PubMed ID: 24919854
[TBL] [Abstract][Full Text] [Related]
15. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
Chiron D; Martin P; Di Liberto M; Huang X; Ely S; Lannutti BJ; Leonard JP; Mason CE; Chen-Kiang S
Cell Cycle; 2013 Jun; 12(12):1892-900. PubMed ID: 23676220
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
17. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
18. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
19. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Zeverijn LJ; Looze EJ; Thavaneswaran S; van Berge Henegouwen JM; Simes RJ; Hoes LR; Sjoquist KM; van der Wijngaart H; Sebastian L; Geurts BS; Lee CK; de Wit GF; Espinoza D; Roepman P; Lin FP; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; de Vos FYFL; van Herpen CML; Gelderblom H; Verheul HMW; Thomas DM; Voest EE
Int J Cancer; 2023 Oct; 153(7):1413-1422. PubMed ID: 37424386
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
